Malecare Offers Free Access to CenterWatch’s Data Base of Clinical Trials for Prostate & Testicular Cancer

Malecare is proud to announce that we are now partnering with the Clinical Trials Resource Center. This partnership allows us to offer you, through our web site (www.malecare.org), CenterWatch’s data base of clinical trials that are being conducted both in the United States and internationally. CenterWatch is the leading publisher of information on clinical research [...]

A New Strategey – Fight Cancer with Cancer – On The Horizon

Thinking out of the box, a new concept to fight cancer, including prostate cancer, has been developed. The strategy is simple, fight cancer with cancer! In a very small phase one trial researchers at the Rogosin Institute have taken encapsulated tumor cells from mice and made a bead from a seaweed-derived sugar called agarose. Then, [...]

Affects of ADT on A Spousal Caregiver of A Man with Advanced Prostate Cancer

We all know it, advanced prostate cancer not only affects the survivor, but it also affects his family. When diagnosed with advanced prostate cancer, the most common treatment is androgen deprivation therapy (ADT) which causes many side effects. These side effects include (but are not limited to) fatigue, nausea, hot flashes, pain, constipation and sexual [...]

Dosing Schedules for ADT, Does It Matter When Treating Men Who Have Prostate Cancer?

One of our biggest disputes around hormone deprivation (ADT) concerns the question of scheduling. Traditionally, ADT involved staying on the therapy drug forever. However, ADT causes significant side effects that negatively impacts both the quality of life as well as posing potential significant medical problems. Over the last five or so years there has been [...]

Long-Term Overall Survival & Metastasis-Free Survival Post Surgery After A Biochemical Recurrence of Prostate Cancer

Researchers at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and the Walter Reed Army Medical Center evaluated metastasis-free survival (MFS) and overall survival (OS) among men with a biochemical reoccurrence (PSA only) of prostate cancer after having received a radical prostatectomy but did not receive additional therapy until developing metastases […]

Go to Top